GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc.
(Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of
cell-engineering platform technologies, today announced the signing
of a clinical and commercial license with Sana Biotechnology, Inc.
(Nasdaq: SANA), a company focused on creating and delivering
engineered cells as medicines.
Under the terms of the agreement, Sana Biotechnology obtains
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related milestone payments.
Doug Doerfler, President and
CEO of MaxCyte, said: "We are delighted to support Sana's
ex vivo cell therapy programs and recognize the potential of
the company's novel hypoimmune cell platform to advance treatments
for serious diseases. This agreement represents an important
achievement for MaxCyte as we continue to expand the use of our
next-generation technology platform to support the development of
innovative treatments."
MaxCyte's ExPERT instrument portfolio represents the next
generation of leading, clinically-validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies to advance innovative cell-based research, development
and potential commercialization of next-generation cell therapies.
The Company's existing customer base ranges from large
biopharmaceutical companies — including 20 of the top 25
pharmaceutical companies based on 2020 global revenue — to hundreds
of biotechnology companies and academic translational centers.
MaxCyte has granted 14 strategic platform licenses to commercial
cell therapy developers that allow for more than 75 clinical
programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
MaxCyte
Contacts:
|
|
|
|
MaxCyte
Inc. Doug Doerfler, Chief
Executive Officer Amanda
Murphy, Chief Financial Officer
|
+1
301-944-1660
|
|
|
Nominated
Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley
Corporate Broking Rupert
Dearden
|
+44 (0)20 7886
2500
|
Joint Corporate
Broker Numis
Securities Limited James
Black / Duncan Monteith / Matthew O'Dowd
|
+44 (0)20 7260
1000
|
|
|
Joint Corporate
Broker Stifel
Nicolaus Europe Limited Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking Nick Adams
|
+44 (0)20 7710
7600
|
|
|
UK IR
Adviser Consilium
Strategic Communications Mary-Jane Elliott Chris Welsh
|
+44 (0)203 709
5700 maxcyte@consilium-comms.com
|
US IR
Adviser Gilmartin
Group David Deuchler,
CFA
|
+1
415-937-5400 ir@maxcyte.com
|
|
|
US Media
Relations Jamie
Lacey-Moreira PressComm PR,
LLC
|
+1
410-299-3310 jamielacey@presscommpr.com
|
View original
content:https://www.prnewswire.com/news-releases/maxcyte-signs-clinical-and-commercial-license-with-sana-biotechnology-301350765.html
SOURCE Maxcyte, Inc.